Aina Oliver-Caldes

Dec 4, 2024 | nature.com | Maximilian Merz |Danai Dima |Nausheen Ahmed |Friedrich Stölzel |Fabian Müller |Aina Oliver-Caldes | +12 more

AbstractDespite the astonishing outcomes after chimeric antigen receptor (CAR) T-cell therapy for relapsed refractory multiple myeloma (RRMM), most patients eventually relapse. There are only limited data available on salvage therapies following relapse after BCMA-directed CAR T-cell therapy.

Dec 4, 2024 | nature.com | Maximilian Merz |Danai Dima |Nausheen Ahmed |Friedrich Stölzel |Fabian Müller |Aina Oliver-Caldes | +12 more

AbstractDespite the astonishing outcomes after chimeric antigen receptor (CAR) T-cell therapy for relapsed refractory multiple myeloma (RRMM), most patients eventually relapse. There are only limited data available on salvage therapies following relapse after BCMA-directed CAR T-cell therapy.

Nov 17, 2024 | onlinelibrary.wiley.com | Aintzane Zabaleta |Noemi Puig |Maria-Teresa Cedena |Aina Oliver-Caldes

1 INTRODUCTION The treatment of patients with multiple myeloma (MM) is being transformed with the development of chimeric antigen receptor (CAR) T cells and T-cell engagers (TCE) targeting antigens such as BCMA and GPRC5D.1-6 These immunotherapies induce responses in heavily pretreated relapsed/refractory MM (RRMM) patients, and in earlier lines of therapy resulted in prolonged progression-free survival (PFS) when compared to standards of care.7, 8 Accordingly, CAR T cells and TCE are being...